Please login to the form below

Not currently logged in
Email:
Password:

morphosys

This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends eight new medicines for EU approval

CHMP recommends eight new medicines for EU approval

The CHMP also adopted a positive opinion for MorphoSys and Incyte’s Monjuvi (tafasitamab) for the treatment of relapsed or refractory diffuse B-cell lymphoma (DLBCL) for patients who are not ... MorphoSys. The CHMP has also recommended approval of

Latest news

More from news
Approximately 6 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.

  • Pharma deals in March 2015 Pharma deals in March 2015

    In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during August 2014 Pharma deals during August 2014

    These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...